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1. Introduction 
In the last decades, the survival of liver transplanted patients and grafts have had a great 
improvement due to many factors. Careful  preoperative evaluation in transplant recipients, 
experience and a multidisciplinary approach have, without any doubt, a major role in the 
selection of candidates and in the diagnosis and treatment of preoperative complications. 
Moreover, with the introduction of new generation immunosuppressive drugs and careful 
pharmacological monitoring, both the episodes of acute rejection and toxic effects have been 
minimized (1) 
In consequence, since the graft and the patient post-transplant survival have been improved, 
the transplanted population has started showing long term medical complications. 
Besides the risk correlated with graft rejection, the transplanted population has an increased 
risk of developing many malignancies. A number of hematologic diseases, skin cancer, 
gastrointestinal tumors  seems to recognize a possible trigger factor in immunosuppressive 
drugs and the patient’s immunological status but also in serological status and viral 
infections quite common in  immunosuppressed patients.  As for frequency, after these two 
groups of complications, cardiovascular diseases are the third cause of death in the 
transplanted population (1) 
Eligibility to liver transplant, once based on Child Pugh system, has been regulated, since a 
few years, by MELD score, an index of survival probability of the end stage liver disease (2). 
This score is obtained on three variables, INR, creatinine and bilirubine. Due to the well 
known inadequate number of available grafts, if compared to patients requiring liver 
transplantation and to the risk of mortality while in the waiting list, this score supplies a 
priority system, based on the severity of the disease, for the organ allocation. The cut off 
value normally considered for eligibility to liver transplantation is a MELD score ≥15. Since 
the evaluation of the MELD score is obtained with this mathematical formula:  
10{0.957Ln(Scr)+0.378Ln(Tbil)+1.12 Ln (INR) +0.643} 
eligibility to transplantation undergoes the parameter of severity of the disease, selecting the 
population of patients with generally worse clinical conditions.  Moreover, the median age 
of the patients waiting for transplantation seems to be higher, essentially due to the 
improvement in the antiviral therapies and the better medical treatment in the hepatological 
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patient; for these reasons, the impairment of the liver function resulting in an eligible score 
can be delayed, with a longer conservative treatment and an older age of the patients who 
undergo liver transplantation.  
Like in general population, the risk of developing cardiovascular disease increases with age, 
but liver disease by itself is often related to cardiovascular disease or higher cardiovascular 
risk factors (2, 3). Therefore, an accurate cardiovascular risk assessment of these patients, 
besides the whole pretransplant evaluation, is essential, both for the increased risk of 
cardiovascular diseases after liver transplant and for the cardiovascular risk assessment of 
the pre-transplant condition. 
2. Pretransplant cardiovascular risk 
Advanced hepatic liver disease is responsible for many changes in the physiology and 
biochemistry of the cardiovascular system, affecting contractility, heart rate, conduction and 
repolarization (4, 5, 6). 
Cirrhotic cardiomyopathy is a pathological condition characterized by an increased cardiac 
output, impaired ventricular response to stress, decreased beta-agonist transduction, 
increased circulating inflammatory mediators with cardio depressant effect, alteration in 
repolarization, low systemic vascular resistance and bradycardia, altered function of 
muscarinic function and beta adrenergic stimulatory system, heart cell membrane 
abnormalities due to altered membrane fluidity and a modified calcium concentration, 
overproduction of nitric oxide, cardio depressant effects of an increased level of carbon 
monoxide (7). 
Both the systolic and diastolic functions seem to be damages: the former, even if in cirrhotic 
cardiomyopathy the cardiac output is high, can be revealed by stress test, and can be caused 
by a reduced cardiovascular reactivity during exercise; the latter determined by fibrosis, 
myocardial hypertrophy and sub endothelial edema results in the impairment of 
compliance and relaxation. (4, 5, 6) 
Abnormalities at the ECG, such electromechanical dissociation, which results in a 
prolongation of the QT interval , and chronotropic incompetence given by an impaired 
response to beta stimulation, are very common in cirrhosis and seem to be mainly related to 
portal hypertension and portosystemic shunting, but also to alterations of the heart rate with 
a central  hypovolemia, loss of renal excretion of water and sodium  and an altered 
baroreflex sensitivity  which contribute to impair the cardiovascular system.(4, 5, 6, 8) 
These conditions can lead to a higher risk of torsade de pointes, rhythm disturbances but 
also to the inability to develop physiologic tachycardia when required. 
Some liver diseases seem to show a correlation also on the coronary blood flow. Diffuse but 
undetectable coronary atherosclerosis, reduced coronary micro vascular bed and impaired 
endothelium function are reported in NAFLD (9, 10). 
Pre-transplant diabetes is another cardiovascular risk factor, and, in liver diseases the 
possibility to find an insulin resistance can be related to the pathogenesis of liver disease ( 
non alcoholic fatty liver disease), where the deregulation of fat metabolism causes an 
overproduction of very low density proteins involved in the metabolic syndrome, and, after 
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the initial over activity with hyperinsulinemia, there is an impairment of islet beta cells; on 
the other hand, the liver glycogenogenesis and glycogenolysis pathways for the regulation 
of carbohydrate metabolism can be impaired due to the hepatic disease itself (10, 11, 12, 13, 
14, 15, 16, 17). 
Renal dysfunction is not uncommon (microalbuminuria, hepato-renal syndrome), and also 
pulmonary heart disease has to be considered such as Hepatopulmonary Syndrome where a 
mismatch between ventilation and perfusion is involved with hypoxemia due to an excess 
of perfusion because of abnormal intrapulmonary vascular dilation. (5, 9, 11, 16) 
Portopulmonary Hypertension, is a condition where pulmonary arterial hypertension is 
associated with liver disease or portal hypertension due to many factors such as 
hyperdinamic circulation, release of mediators from the congested bowel because of 
splancnic overload, vasoconstriction and remodeling of the lung vascular endothelium.(16) 
The American Association for the Study of Liver Diseases (2) recommends a rigorous pre-
operative Assessment 
 
CAD= coronary artery disease; CTA= computed tomography angiogram; ECG= electrocardiogram; H= 
heart failure; LV= left ventricular; LVOTO= left ventricular outflow tract obstruction; POPH= 
portopulmonary hypertension; Pulm.= pulmonary; QTc= corrected QT interval; RV= right ventricular; 
TTE= transthoracic 
Fig. 1. Suggested strategy for pre-operative cardiac assessment of liver transplant candidates 
3. Post transplant cardiovascular risk  
Patients who undergo liver transplantation have an around doubled risk of developing 
cardiovascular disease if compared to non transplanted population. To investigate the risk of  
such complications, multiple risk factors have to be added up. On one hand, there are all the 
risk factors of the general population such as advanced age, male gender, smoking history, 
high body mass index, pre-transplant diabetes mellitus, marital status. On the other hand, 
some peculiar risk related to the etiology of the underlying liver cirrhosis have to be 
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considered, since liver disease  caused by criptogenetic, alcohol and hepatitis C seems to be 
related to an increased cardiovascular risk. Moreover, after transplantation, a new 
physiological condition arises from the hemodynamic, biochemical and drug related 
standpoint. The vasodilatation existing in the cirrhotic patient has been solved and a systemic 
vasoconstriction is quite often present in the transplanted patient. Many factors seem to be 
involved in such systemic resistance modification but a definite pathogenesis is still under 
debate. The renin-angiotensin system seems to be involved but also the effect of endothelin, 
which seems to be higher then normal after LT, with its vasoconstrictor effect and which could 
determine the arterial pressure increase as well as the arterial stiffness which are clearly related 
to high pressure. Anyway a high arterial blood pressure before transplant seems to be a factor 
contributing the post transplant development of arterial hypertension (1, 18, 19) 
The metabolic syndrome is apparently another risk factor, quite common in transplanted 
patient. In liver cirrhosis the patient generally suffers from a hypermetabolic condition and 
insulin resistance is very common. The normalization of the metabolic status, and the 
change induced in the metabolism of lipoproteins, in absence or combined with insulin 
resistance or diabetes due to the pancreas cells function impairment, can explain some 
effects of the post-transplant status while the underlying liver disease itself (HCV infection 
and relapse) seems to be related to diabetes affecting the insulin pathway and directly 
affecting the pancreatic beta cells (20, 21, 22, 23) 
A major role in the cardiovascular risk factors lies in the irreplaceable use of 
immunosuppressive drugs (1, 18, 24) 
Immunosuppressive drugs are related to arterial hypertension, and especially calcineurin 
inhibitors, have turned out to affect the vascular bed causing endothelial dysfunction. 
Besides their direct effect on the vascular endothelium, they also affect the vascular smooth 
muscle cells and have effects on the release and production of nitric oxide and endotheline. 
The renal function is impaired because of the nephrotoxic effects of many of these drugs that 
cause an impairment of the glomerular filtration rate and side effects on arterial pressure. 
Immunosuppressive drugs have also a pancreatic beta cells toxicity leading to a decrease in 
the production and secretion of insulin and an increased risk of diabetes (18). This condition 
by itself impairs the micro vascular bed and renal function. These drugs, especially M-tor 
inhibitors, affect the lipid metabolism, with the development of high levels of cholesterol 
and triglyceride concentration requiring lipid-lowering drugs. This side effect seems to be 
due to a decreased drug related bile acid synthesis but also to the agonist effects of some 
immunosuppressive drugs with low density lipoprotein cholesterol receptors, with a higher 
quantity of circulating low density lipoprotein. These side effects cause a further impairing 
in the vascular beds status, with effects of stiffness on the vascular walls. Also the steroids, 
frequently used in combination with immunosuppressive drugs or as treatment of acute 
rejection, have their well known effects on the vascular system, causing vasoconstriction, 
arterial hypertension, truncal fat deposition, and on the glucydic metabolism, causing a 
decreased insulin production, and impairing the peripheral glucose utilization, resulting in 
an insulin resistance or diabetes (1, 18, 25, 26). 
4. Immunosuppression and cardiovascular risk factors 
Transplantation soared in the 1980s thanks to the introduction of a new immunosuppressive 
drug: Cyclosporine. Before that, survival after liver transplantation was strongly impaired 
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by the common onset of rejection and graft loss, when the immunosuppressive strategies 
were poor and crude such as the whole-body x-radiation at the very beginning (1960s) and 
azathioprine, prendisolone and anti-lymphocytes antibodies about ten years later. (27) 
The experience in liver transplant shows that liver transplant recipients develop a lower rate 
of rejection if compared to other organs (heart, kidney) possibly because a form of 
microchimerism due to a large number of donor’s cells within the allograft. Also the 
production by the liver of soluble donor MHC class 1 molecules has been mentioned to 
explain this resistance to rejection in liver transplantation. The size and regenerative 
properties of liver can also play a role.(27, 28) 
Nevertheless, although the liver is less prone to rejection then other organs, the 
immunosuppressive regimen remains mandatory after liver transplantation. The selection of 
immunosuppressive drugs is not universal but has to be done considering the pretransplant 
history and the medical conditions, considering for example pretransplant poor renal 
function, diabetes or hepatocellular carcinoma. Therefore a careful balance between pros 
and cons is essential. 
At present, calcineurin inhibitors are the most large used immunosuppressive drugs for 
liver transplantation, with well known side effects such as neurotoxicity, nephrotoxicity, 
hypertension, increased risk of death due to cardiovascular risk factors, gingival 
hyperplasia, hirsutism and diabetes. 
 Cyclosporine, the oldest one, is derived from the fungus Tolypocladium inflatum and is a 
polypeptide of 11 amino acids. Tacrolimus, the most recent one, is derived from 
Streptomyces tsukabaensis and is a macrolide compound. 
Cyclosporine inhibits interleukin 2 gene transcription, binding cyclophilin, inhibiting the 
calcium/calmodulin phosphatase dependent calcineurin complex. It causes a 
dephosphorilation of activated T cell which is important for the transcription of cytokines 
for the activation of  T cells, while Tacrolimus, from the same group of immunosuppressive 
drugs and with a similar mechanism of action, inhibits calcineurin binding to another 
specific immunophilin, FK binding protein 12. (27, 28, 29) 
These drugs seem to have complex activities besides immunosuppression, causing 
endothelial dysfunction and more specifically a decrease in the production of the 
vasodilator nitric oxide (NO) by endothelial NO synthase (eNOS), affecting the vasodilator 
function by negatively altering endothelial intracellular Ca2+ and eNOS phosphorylation. 
Ca2+ concentration is altered by intracellular Ca2+ leak and decreased agonist-induced 
intracellular Ca2+ release which negatively affects eNOS phosphorylation, NO production, 
and endothelium-dependent dilatation. The precise mechanisms leading to hyperlipidemia 
are not completely known. There are contributing factors such as corticosteroids use and 
obesity. Anyway cyclosporine is related to an increase of VLDL and LDL while Tacrolimus 
seems to be characterized by VLDL increase alone. The mechanisms which underlie these 
side effects seem to be the increase in free intracellular cholesterol levels due to an impaired 
cholesterol esterification, but also the activation of the transcription factor responsible for 
the expression of lipid related genes. Oxidative processes may also underlie the 
atherosclerotic effect. 
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The nephrotoxic effects are well known, and they can by themselves be related to the 
development of arterial hypertension. The mechanism, beside a possible involvement of the 
tubular epithelium, seems to be more strongly related to vascular alteration of the afferent 
arterioles, with consequent ions alteration and hyperkaliemia. (28, 29, 30) 
The arteriolar vasoconstriction and renal ischemia are related to an imbalance between the 
vasoactive messengers ( endothelin-1 and tromboxane A2), the dysregulation of nitric-oxide 
formation and the renin-angiotensin system. Besides these vascular effects altering the renal 
control of arterial pressure, the nephrotoxic direct effects should also be mentioned, with 
tubular cell apoptosis and necrosis, but also the effects on the cell cycle compromising the 
proliferation capacity and accelerating cell aging possibly mediated by an oxidative stress 
caused by reactive oxygen species (ROS) and lipid peroxides. This effect has been 
demonstrated as an abnormality in permeability of the mitochondria causing an isometric 
vacuolization resulting in the presence of giant mitochondria. Thus, the endoplasmic 
reticulum undergoes enlargement and the proteic syntesis is affected. Cyclosporine can act 
as an endoplasmic reticulum stress inducer causing epithelial phenotypic changes leading to 
nephrotoxicity (30, 31, 32, 33, 34). 
Endoplasmic reticulum stress seems to play a major role in many diseases such as 
atherosclerosis, Alzheimer, diabetes and inflammatory bowel diseases, leading the unfolded 
protein response to an adaptative response. (35, 36) 
The above mentioned stress is involved in post transplant diabetes, promoting insulin 
resistance and cells death. Insulin secerning cells undergo proteins synthesis stress and are 
very sensitive to any status causing accumulation of anomalous proteins. The 
pathophisiology of pancreatic beta cells damage during treatment with Tacrolimus and 
Cyclosporine is still matter of debate, but it seems related to the endoplasmic reticulum 
stress which modify cells vitality, since in animal models treated with calcineurin inhibitors, 
nuclear inclusions, dilatation in cistern of the granulous endoplasmic reticulum with 
degranulation and degeneration of pancreatic beta islets have been shown (35, 36) 
Steroids are often used in immunosuppressive therapeutic schemes in the perioperative 
period, both intraoperatively, and after transplantation for a period ranging from 3 to 6 
months for liver transplantation. Moreover, at the possible onset of acute rejection, bolus of 
steroids are administered. The steroid immunosuppressive function derives from the  
inactivation of the response of lymphocytes and macrophages by inhibiting the production 
of cytokines, but also suppressing antigens and stimulating the migration of T cells to the 
lymphoid tissue.(30) 
A large body of evidence supports the theory that steroids induce an imbalance between 
vasoconstriction and vasodilatation, favoring vasoconstriction, resulting in arterial 
hypertension. 
The increased vasoconstriction is mediated by several mechanisms. In large part 
vasoconstriction is mediated by the increased endothelin-1 synthesis and secretion, 
increased erythropoietin levels by the increased level of cytosolic calcium, increased 
sympathetic activity that is mediated by the increase of Beta1-adrenergic receptor expression 
and increased synthesis of catecholamines, by the increased expression of various enzymes 
involved in the catecholamines biosynthesis including tyrosine hydroxilase and phenyl 
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ethanolamine N-methyltransferase and altered availability of Alfa1-adrenergic receptors in 
vascular smooth muscles, leading to an increased vascular reactivity, pressure 
responsiveness and hypertension. The vasoconstriction and hypertension induced by 
steroids are also mediated through enhanced synthesis and action of vasoactive substances 
and their receptors, including neuro peptide Y (NPY), arginine vasopressin (AVP) and atrial 
natriuretic peptide (ANP).  
Another interesting issue is the role of the renin-angiotensin system activation in the 
development of steroids induced hypertension. Steroids act directly at the liver site, 
enhancing the synthesis of angiotensinogen. (29, 37) 
On the other hand, steroids negatively affect various vasodilatory systems causing nitric 
oxide (NO) deficiency through a range of a negative influences on the NO biosynthetic 
pathways involving alteration  in  the activity and expression of NO synthase, decreased 
availability of tetrahydrobiopterin (BH4) and decreased NO precursor L-arginine. Moreover 
steroids affect the production of other vasodilatatory substances as prostacyclin, 
prostaglandin E2 and kallikrein. 
Steroids induce insulin resistance in skeletal muscle by directly interfering with the insulin 
signaling cascade. The same effect is produced also in hepatic cells and thus endogenous 
glucose production is increased. (28, 29, 37) 
Steroids appear to have a direct causal effect relationship with cardiovascular disease 
depending on dose, duration, cumulative dose of exposure and route of administration. The 
increased risk is mediated through the induction of several risk factors for cardiovascular 
disease. 
Since the late 1990s other immunosuppressive drugs have been introduced into the world of 
transplantation: the group of m-Tor inhibitors (Sirolimus and Everolimus) (27, 28, 29). 
Sirolimus is derived from actinomycete Streptomyces hygroscopicus. It has a homologous 
structure if compared to Cyclosporine and Tacrolimus and it also binds to FK bindig 
proteins family (FKBP-12) which binds to mammalian targets of rapamycin (MTOR) which 
has a kinase activity. Sirolimus plays its action on the signal transduction pathway, blocking 
the IL-2 and IL-5 induction of B and T cell proliferation. It inhibits the normal cell 
proliferation in response to IL-2. Everolimus, is a macrolide derived from Sirolimus, with a 
similar mechanism of action, inhibiting the activation of immunophyllin FKBP-12. Unlike 
Sirolimus it has pharmacokinetics properties which make it easier to handle.  
These drugs are particularly interesting and under debate. Based on their anti proliferative 
effects, they also seem to have anti-neoplastic effects based on the fact that they inhibit 
angiogenesis, inhibit cancer cells survival and also cancer stem cells survival (27, 28, 29). 
They seem to have less nephrotoxic effects than calcineurin-inhibitors provided there is no 
pre-existing renal disease, basing their action on m-Tor contrasting the renal fibrosis caused 
by TGF-beta. There’s anyway a risk of proteinuria or of renal damage amplification in an 
already compromised renal function. 
They show interesting properties in promoting tolerance but Sirolimus is considered an 
unsafe drug for the 1st month after transplantation for a higher risk of developing  hepatic 
artery thrombosis and for a slower and more difficult wounds healing. Mouth ulcers and leg 
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edema are common. It’s strongly related to high risk of developing of hyperlipidemia which 
seems to be caused by an increased hepatic secretion of VLDL, increased hepatic synthesis 
of apoB100 and a reduction in the hepatic catabolism of LDL. The action of lipoprotein 
lipase is decreased and the expression of apoCIII and lipase in adipose tissue are increased. 
Anyway these drugs have effects on macrophages and antiproliferative effects which could 
protect from the cardiovascular risk of atherosclerosis (27, 28, 29, 38, 39). 
Antimetabolites such as mycophenolate mofetil and mycophenolate sodium have 
immunosuppressive properties which were recognized in the 1990s although these drugs 
are older. Their action derive from the blockage of inosine-51-monophosphate deydrogenase 
(IMPDH) resulting in the selective lymphocyte proliferation blockage. They have probably 
less cardiovascular side effects, mainly gastrointestinal disorders, bone marrow depression, 
some infections. Their exclusive use is hardly ever considered due to their insufficient 
protection from acute rejection if not combined to m-Tor or CNI. Yet their use anyway often 
allows a lower CNI or m-Tor dosage with side effects sparing properties. (27, 28, 29, 40) 
Both polyclonal and monoclonal antibodies [ anti- thymocites globilin (ATG), anti-
lymphocyte globulin (ALG), monoclonal antibodies (OKT3, Campath, Basiliximab)] are also 
largely used  in combination with CNI or m-Tor delayed introduction as induction 
therapies, minimizing the side effects of CNI and m-Tor inhibitors.  
Other immunosuppressive drugs are currently undergoing trials such as Belatacept, which 
inhibits T cell activation binding CD80 and CD86, and looks promising, with less renal 
toxicity, and Efalizumab which inhibits T cell-APC stabilization and blocks lymphocyte 
adhesion to endothelial cells, with good results as for immunosuppressive properties but 
with an increased risk of onset of post-transplant lymphoproliferative disorders (27, 28, 29). 
5. Risk of new onset of diabetes (36) 
 
 
 African American, 
Hispanic 
 Age > 40–45 yrs 
 Recipient male gender 
 Family history of DM 
 HLA A30, B27, B42 
 HLA mismatches 
 HCV 
 CMV 
 Pre-tx IFG/IGT 
 Proteinuria 
 HypoMg 
Individualization of 
Immunosuppressive 
therapy 
 Tacrolimus 
 Cyclosporine 
 Corticosteroid 
 mTOR inhibitors 
 Anti CD25 mAB? 
NON-MODIFIABLE MODIFIABLE POTENTIALLY MODIFIABLE
LEGEND: 
IGT: impaired glucose tolerance, IFG: impaired fasting glucose, Anti CD25 mAb, Anti CD25 
monoclonal antibody, CMV:cytomegalovirus, HCV: hepatitis C, HypoMg: hypomagnesemia, Pre-
Tx: pre-transplant 
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IMMUNOSUPPRESSIVE AGENT MECHANISM OF ACTION 
 
  
CALINEURINE INHIBITORS Inhibit signal 2 trasduction via T cell 
receptor 
 
  
MAMMALIAN TARGET OF RAPAMYCIN 
INHIBITORS 
Inhibit Signal 3 trasduction via IL-2 receptor 
 
  
 
MYCOPHENOLIC ACID Inhibit purine and DNA synthesis 
 
  
CORTICOSTEROIDS  Inhibit cytokine transcription by antigen 
presenting cell; 
Selective lysis of immature cortical 
thymocytes 
  
AntiCD3 monoclonal antibodies 
 
Depletion and receptor modulation in T cell 
Interferes with Signal 1 
Antithymocyte globuline 
 
Depletion and receptor modulation in T cells 
Interferes with Signal 1, 2, 3 
Inhibits lymphocytes trafficking 
Anti IL-2 alpha chain receptor antibodies 
 
Inhibit T cell proliferation to IL-2  
 
  
Anti –CD52 monoclonal antibodies  
 
Cause depletion of thymocytes, T cells, B 
cells and monocytes 
 
IMMUNOSUPPRESSIVE AGENT SIDE EFFECTS 
 
  
CALINEURINE INHIBITORS Hypertension, Renal toxicity, neurotoxicity, diabetes, 
dislipidemia, gingival hyperplasia, hirsutism. 
 
  
MAMMALIAN TARGET OF 
RAPAMYCIN INHIBITORS 
Dislipidemia, anemia, leucopenia, thrombocytopenia, 
HAT, wound dehiscence, aphtous ulcers, arthralgia, 
proteinuria 
 
  
MYCOPHENOLIC ACID Anorexia, abdominal pain, gastritis, diarrhea, 
neutropenia 
  
www.intechopen.com
 
Recent Advances in Cardiovascular Risk Factors 
 
46
CORTICOSTEROIDS  Hypertension, pancreatitis, peptic ulcer, osteoporosis, 
aseptic necrosis of femoral head, diabetes, 
hyperlipidemia, risk of infections, difficult wound 
healing 
  
AntiCD3 monoclonal antibodies 
 
Fever, hypotension, headache, aseptic meningitis, 
dyspnea, vomiting, diarrhea 
  
Antithymocyte globuline 
 
Leucopenia, thrombocytopenia 
 
  
Anti IL-2 alpha chain receptor 
antibodies 
 
Risk of acute rejection 
  
Anti –CD52 monoclonal 
antibodies  
Risk of acute rejection 
6. Conclusions 
Besides the cardiovascular risk factors related to age, family disease and life habits, the 
transplant candidate has a particular hemodynamic, biochemical, cardiac and systemic 
condition depending on the hepatic disease. After transplantation, these paraphysiologic 
modifications suddenly change, with the onset of a new systemic condition, the appearance 
of organ damages not evident before, a new risk factors profile related to the new situation 
and to unavoidable life-saving drugs treatment. 
For these reasons the pre-transplant cardiovascular evaluation and the post-transplant 
accurate monitoring followed by a careful choice of the immunosuppressive therapeutic 
regimen, drug level monitoring, educational efforts to ameliorate life style and risk factors  
are mandatory for a satisfactory outcome.  
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